NATCO Pharma First Quarter 2026 Earnings: Misses Expectations

Simply Wall St
NSEI:NATCOPHARM 1 Year Share Price vs Fair Value
Explore NATCO Pharma's Fair Values from the Community and select yours

NATCO Pharma (NSE:NATCOPHARM) First Quarter 2026 Results

Key Financial Results

  • Revenue: ₹13.9b (up 2.1% from 1Q 2025).
  • Net income: ₹4.81b (down 28% from 1Q 2025).
  • Profit margin: 35% (down from 49% in 1Q 2025). The decrease in margin was driven by higher expenses.
  • EPS: ₹26.84 (down from ₹37.32 in 1Q 2025).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

NSEI:NATCOPHARM Earnings and Revenue Growth August 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

NATCO Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 25%.

Looking ahead, revenue is expected to decline by 17% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 10%.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 1.5% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for NATCO Pharma (1 is a bit unpleasant!) that you should be aware of before investing here.

Valuation is complex, but we're here to simplify it.

Discover if NATCO Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.